Responses
Regular and young investigator award abstracts
Clinical trials in progress
316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A
Compose a Response to This Article
Other responses
No responses have been published for this article.
